Acute Cardiovascular Effects of Marijuana Use

Ghasemiesfe, Mehrnaz; Ravi, Divya; Casino, Thomas; Korenstein, Deborah; Keyhani, Salomeh

doi:10.1007/s11606-019-05235-9

Cited by 14 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose dependent effect of THC on HR, and lack of effect on BP, in our study is consistent with past reports of cannabinoids increasing HR without significantly affecting BP (Ashton, 2001;Beaconsfield et al, 1972;Ghasemiesfe et al, 2020;Hunault et al, 2008;Lex et al, 1984;Kanakis et al, 1976;Wachtel et al, 2002). Our findings are also consistent with reports that the degree of tachycardia is related to the dosage of THC in both smoked cannabis (Hunault et al, 2008;Johnson & Domino, 1971) and after oral THC (Kirk & de Wit, 1999;Pabon & de Wit, 2019;Wachtel et al, 2002).…”

Section: Discussionsupporting

confidence: 93%

Acute effects of oral delta‐9‐tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects

et al. 2021

View full text Add to dashboard Cite

Cannabis is the most commonly used psychotropic drug in the United States, after alcohol (SAMHSA, 2019). Due to ongoing state legalization of medicinal and, in some cases, recreational cannabis, both accessibility and use of the drug are increasing. Despite its apparent sedative and calming effects, cannabis and its main psychoactive constituent, ∆ 9 -tetrahydrocannabinol (THC), can also produce serious adverse effects including tachycardia and anxiety

show abstract

Section: Discussionsupporting

confidence: 93%

Acute effects of oral delta‐9‐tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Capturing all modalities of use may be particularly important for some outcomes (e.g., blood pressure) given the hemodynamic effects of cannabis. 5 In addition, while the main exposure variable proposed for this cohort is use in the past 30 days, our data suggest that use patterns vary significantly among current users. Illustrating the importance of assessing frequency of current use, some participants reported using less than 10 times per month (e.g., weekend user) while about half reported using daily with an average frequency of almost 4 times per day.…”

Section: Discussionmentioning

confidence: 71%

“…Endocannabinoid receptors are ubiquitous in the cardiovascular system. Cannabis use is associated with tachycardia, 5 increased myocardial oxygen demand and platelet activation, as well as endothelial dysfunction and oxidative stress. [6][7][8][9] Moreover, smoking cannabis (the predominant method of consumption) 10 increases blood carboxyhemoglobin concentrations, and does so at a fivefold higher level than tobacco smoke.…”

Section: Introductionmentioning

confidence: 99%

The Heart and Cannabis (THC) Cohort: Differences in Baseline Health and Behaviors by Cannabis Use

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Evidence on the cardiovascular health effects of cannabis use is limited. We designed a prospective cohort study of older Veterans (66 to 68 years) with coronary artery disease (CAD) to understand the cardiovascular consequences of cannabis use. We describe the cohort construction, baseline characteristics, and health behaviors that were associated with smoking cannabis. Objective To understand the cardiovascular consequences of cannabis use. Design We designed a prospective cohort study of older Veterans (66 to 68 years) with CAD. Participants A total of 1,015 current cannabis smokers and 3,270 non-cannabis smokers with CAD. Main Measures Using logistic regression, we examined the association of baseline variables with smoking cannabis in the past 30 days. Results The current cannabis smokers and non-current smokers were predominantly male (97.2% vs 97.1%, p=0.96). Characteristics associated with recent cannabis use in multivariable analyses included lack of a high school education (odds ratio [OR] 2.15, 95% confidence interval [CI]: 1.10 to 4.19), financial difficulty (OR 1.47, 95% CI: 1.02 to 2.11), tobacco use (OR 3.02, 95% CI: 1.66 to 5.48), current drug use (OR 2.82, 95% CI: 1.06 to 7.46), and prior drug use (OR 2.84, 95% CI: 2.11 to 3.82). In contrast, compared to individuals with 0 to 1 comorbid conditions, those with 5 chronic conditions or more (OR 0.43, 95% CI: 0.27 to 0.70) were less likely to smoke cannabis. Conclusions In this older high-risk cohort, smoking cannabis was associated with higher social and behavioral risk, but with fewer chronic health conditions.

show abstract

“…Multiple studies confirmed the increased heart rate after Δ 9 -THC administration, which was homogeneous irrespective of routes of administration – oral, intravenous, or inhaled. 93 , 94 , 112 , 113 Thus, further studies should be conducted to update and verify the above-mentioned results and determine the exact effect of the CBC on the cardiac muscle as well as vasculature, which would substantially broaden the knowledge in this area.…”

Section: Pcbsmentioning

confidence: 98%

“… ↑, increase; ↓, decrease; Δ 9 -THC, Δ 9 -tetrahydrocannabinol; CBD, cannabidiol; HUASMC, Human Umbilical Artery Smooth Muscle Cells; VSMC, vascular smooth muscle cell. 43 , 53 , 55 , 92 – 94 , 138 , 140 , 142 – 144 , 146 , 147 …”

Section: Cvdsmentioning

confidence: 99%

How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases

Dziemitko

Harasim-Symbor

Chabowski

2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Cardiovascular disease (CVD) causes millions of deaths worldwide each year. Despite the great progress in therapies available for patients with CVD, some limitations, including drug complications, still exist. Hence, the endocannabinoid system (ECS) was proposed as a new avenue for CVDs treatment. The ECS components are widely distributed through the body, including the heart and blood vessels, thus the action of its endogenous and exogenous ligands, in particular, phytocannabinoids play a key role in various pathological states. The cardiovascular action of cannabinoids is complex as they affect vasculature and myocardium directly via specific receptors and exert indirect effects through the central and peripheral nervous system. The growing interest in phytocannabinoid studies, however, has extended the knowledge about their molecular targets as well as therapeutical properties; nonetheless, some areas of their actions are not yet fully recognized. Researchers have reported various cannabinoids, especially cannabidiol, as a promising approach to CVDs; hence, the purpose of this review is to summarize and update the cardiovascular actions of the most potent phytocannabinoids and the potential therapeutic role of ECS in CVDs, including ischemic reperfusion injury, arrhythmia, heart failure as well as hypertension.

show abstract

Acute Cardiovascular Effects of Marijuana Use

Cited by 14 publications

References 4 publications

Acute effects of oral delta‐9‐tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects

Acute effects of oral delta‐9‐tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects

The Heart and Cannabis (THC) Cohort: Differences in Baseline Health and Behaviors by Cannabis Use

How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases

Contact Info

Product

Resources

About